NXP-2 Positive Dermatomyositis with Marked Dysphagia Following an Insect Bite

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2024 Jul 11

PMID 38991369

Authors

Larissa M Bombardi

Carla Alexandra Scorza

Josef Finsterer

Fulvio Alexandre Scorza

Affiliations

Soon will be listed here.

References

Yan T, Zhang X, Yang H, Sun W, Liu L, Du Y . Association of anti-NXP2 antibody with clinical characteristics and outcomes in adult dermatomyositis: results from clinical applications based on a myositis-specific antibody. Clin Rheumatol. 2021; 40(9):3695-3702. DOI: 10.1007/s10067-021-05667-x. View

Takahashi K, Yoshida N, Murakami N, Kawata K, Ishizaki H, Tanaka-Okamoto M . Dynamic regulation of p53 subnuclear localization and senescence by MORC3. Mol Biol Cell. 2007; 18(5):1701-9. PMC: 1855011. DOI: 10.1091/mbc.e06-08-0747. View

SZOBOR A, Simon K, Szigeti A . [Fulminating fatal dermatomyositis and myasthenia gravis after a bee sting (clinicopathological study)]. Morphol Igazsagugyi Orv Sz. 1985; 25(3):207-12. View

Fredi M, Cavazzana I, Ceribelli A, Cavagna L, Barsotti S, Bartoloni E . An Italian Multicenter Study on Anti-NXP2 Antibodies: Clinical and Serological Associations. Clin Rev Allergy Immunol. 2022; 63(2):240-250. PMC: 9464148. DOI: 10.1007/s12016-021-08920-y. View

Ichimura Y, Konishi R, Shobo M, Inoue S, Okune M, Maeda A . Anti-nuclear matrix protein 2 antibody-positive inflammatory myopathies represent extensive myositis without dermatomyositis-specific rash. Rheumatology (Oxford). 2021; 61(3):1222-1227. DOI: 10.1093/rheumatology/keab518. View

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L . Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken). 2017; 69(11):1771-1776. PMC: 5509530. DOI: 10.1002/acr.23188. View

Xu S, Hu X, Wang J, Xu Q, Han Z, Zhou H . Polymyositis and dermatomyositis biomarkers. Clin Chim Acta. 2023; 547:117443. DOI: 10.1016/j.cca.2023.117443. View

Li L, Liu C, Cheng L, Yan S, Chen H, Li Y . Assessment of diagnostic utility, clinical phenotypic associations, and prognostic significance of anti-NXP2 autoantibody in patients with idiopathic inflammatory myopathies: a systematic review and meta-analysis. Clin Rheumatol. 2020; 40(3):819-832. DOI: 10.1007/s10067-020-05291-1. View

Ceribelli A, Isailovic N, De Santis M, Generali E, Fredi M, Cavazzana I . Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis. Clin Rheumatol. 2016; 36(2):469-475. DOI: 10.1007/s10067-016-3453-0. View

10.

Didona D, Solimani F, Caposiena Caro R, Sequeira Santos A, Hinterseher J, Kussini J . Dermatomyositis: a comprehensive review of clinical manifestations, serological features, and therapeutic approaches. Ital J Dermatol Venerol. 2023; 158(2):84-98. DOI: 10.23736/S2784-8671.23.07458-3. View

11.

Manwatkar A, Padiyar S, Nair A, Jha A, Kumar S, Yadav B . Clinical profile of anti-NXP-2 antibody-positive inflammatory myositis and outcome in an Indian population. Clin Rheumatol. 2023; 42(12):3289-3297. DOI: 10.1007/s10067-023-06751-0. View

12.

Wang X, Ding Y, Zhou Z, Hou J, Xu Y, Li J . Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children. Pediatr Rheumatol Online J. 2021; 19(1):6. PMC: 7788734. DOI: 10.1186/s12969-020-00492-z. View